Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Exploratory Study of a HIPEC Priming Strategy Followed by Serplulimab Combined With SOX/XELOX as Neoadjuvant Therapy for Locally Advanced Gastric Cancer

NCT07621484 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.

NCT NCT07621484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07621484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Exploratory Study of a HIPEC Priming Strategy Followed by Serplulimab Combined With SOX/XELOX as Neoadjuvant Therapy for Locally Advanced Gastric Cancer
Lead sponsor
Shanghai Changzheng Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
May 9, 2028
Enrollment
48 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, locally advanced gastric cancer